
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8789849/publications.pdf Version: 2024-02-01



MOSHE TALDAZ

#	Article	IF	CITATIONS
1	Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 17-23.	0.2	9
2	Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 –) Tj ETQq0 0 (2022, 22, 336-346.) rgBT /Over 0.2	lock 10 Tf 50 5
3	Epigenetic Downregulation of Socs2 Contributes to Mutant N-Ras-Mediated Hematopoietic Dysregulation. DMM Disease Models and Mechanisms, 2022, , .	1.2	4
4	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinaseâ€2 (<scp>JAK2</scp>), in patients with myelofibrosis and low pretreatment platelet counts. British Journal of Haematology, 2022, 198, 317-327.	1.2	18
5	The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nature Communications, 2022, 13, .	5.8	22
6	A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. Blood Reviews, 2021, 45, 100691.	2.8	17
7	Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia, 2021, 35, 1-17.	3.3	116
8	The Interferon-Alpha Revival in CML. Hematologic Malignancies, 2021, , 197-226.	0.2	0
9	Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma. Oncotarget, 2021, 12, 160-172.	0.8	8
10	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncology, 2021, 7, 525-533.	3.4	65
11	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. HemaSphere, 2021, 5, e553.	1.2	7
12	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. HemaSphere, 2021, 5, e562.	1.2	20
13	Mechanism of mutant calreticulin-mediated activation of the thrombopoietin receptor in cancers. Journal of Cell Biology, 2021, 220, .	2.3	8
14	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood, 2021, 138, 2042-2050.	0.6	95
15	Remembering Emil J. Freireich: A Portrait of Courage and Innovation in Cancer Research—March 16, 1927 to February 1, 2021. Journal of Clinical Oncology, 2021, 39, 2973-2976.	0.8	3
16	Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Advances, 2021, 5, 5047-5056.	2.5	10
17	A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis. Blood, 2021, 138, 139-139.	0.6	10
18	Efficacy of HMA +/- Venetoclax or Intensive Chemotherapy in Blast-Phase Myeloproliferative Neoplasms. Blood, 2021, 138, 2569-2569.	0.6	2

#	Article	IF	CITATIONS
19	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Advances, 2020, 4, 4282-4291.	2.5	77
20	Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Advances, 2020, 4, 5825-5835.	2.5	60
21	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clinical Cancer Research, 2020, 26, 1247-1257.	3.2	54
22	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure. American Journal of Hematology, 2020, 95, 594-603.	2.0	96
23	Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1385-1415.	2.3	147
24	Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 45-46.	0.6	1
25	Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate-Âor High-Risk Myelofibrosis (MF) and Low Platelet Counts. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S355.	0.2	6
26	The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia, 2019, 33, 2924-2933.	3.3	49
27	SOHO State of the Art Updates and Next Questions: Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 191-199.	0.2	1
28	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leukemia Research, 2019, 79, 38-44.	0.4	25
29	Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematology,the, 2019, 6, e630-e637.	2.2	194
30	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine, 2019, 381, 2315-2326.	13.9	257
31	Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. Oncogene, 2019, 38, 1576-1584.	2.6	62
32	Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1036-1042.	0.6	1
33	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood, 2019, 134, 670-670.	0.6	42
34	Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates deubiquitinase USP5 in tumor cells. Oncotarget, 2019, 10, 5745-5754.	0.8	10
35	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. JAMA Oncology, 2018, 4, 652.	3.4	261
36	Dasatinib dose management for the treatment of chronic myeloid leukemia. Cancer, 2018, 124, 1660-1672.	2.0	19

#	Article	IF	CITATIONS
37	Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth. Neoplasia, 2018, 20, 152-164.	2.3	22
38	Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. Annals of Hematology, 2018, 97, 573-584.	0.8	7
39	Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood, 2018, 132, 293-306.	0.6	45
40	Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e201-e210.	0.2	0
41	Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018, 132, 393-404.	0.6	392
42	Oncologists' Use of Genomic Sequencing Data to Inform Clinical Management. JCO Precision Oncology, 2018, 2, 1-13.	1.5	4
43	Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1500-1537.	2.3	41
44	Genomic Landscape and Clinical Features of Triple-Negative Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S268.	0.2	1
45	Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1108-1135.	2.3	179
46	The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leukemia Research, 2018, 70, 91-96.	0.4	20
47	Primary myelofibrosis evolving to an aplastic appearing marrow. Clinical Case Reports (discontinued), 2018, 6, 1393-1395.	0.2	2
48	Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. Journal of Hematology and Oncology, 2018, 11, 101.	6.9	20
49	Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity. Blood, 2018, 132, 4324-4324.	0.6	1
50	Induction of p53 suppresses chronic myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 2165-2175.	0.6	10
51	Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica, 2017, 102, 327-335.	1.7	87
52	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of Hematology and Oncology, 2017, 10, 55.	6.9	302
53	Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma. Nature Communications, 2017, 8, 14449.	5.8	51
54	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 684-695.e6.	0.2	42

#	Article	IF	CITATIONS
55	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematology,the, 2017, 4, e317-e324.	2.2	243
56	Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. American Journal of Hematology, 2017, 92, 555-561.	2.0	12
57	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica, 2017, 102, 519-528.	1.7	22
58	Characterization of Mortality in Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S353.	0.2	1
59	NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1193-1207.	2.3	119
60	New Series: SOHO †State of the Art Updates and Next Questions'. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 463.	0.2	0
61	Integrative clinical genomics of metastatic cancer. Nature, 2017, 548, 297-303.	13.7	685
62	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget, 2017, 8, 89848-89866.	0.8	45
63	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 612-621.	5.1	214
64	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood, 2016, 127, 2693-2700.	0.6	66
65	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood, 2016, 127, 703-712.	0.6	87
66	Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. Leukemia and Lymphoma, 2016, 57, 2259-2267.	0.6	16
67	Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leukemia Research, 2016, 48, 84-91.	0.4	130
68	The Interferon Alpha Revival in CML. Hematologic Malignancies, 2016, , 207-230.	0.2	0
69	A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis. Tomography, 2016, 2, 67-78.	0.8	13
70	Meir Wetzler, MD. Cancer, 2015, 121, 2106-2107.	2.0	0
71	Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 424-434.	2.3	24
72	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. Journal of Translational Medicine, 2015, 13, 294.	1.8	36

#	Article	IF	CITATIONS
73	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 2015, 100, 479-488.	1.7	246
74	Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood, 2015, 125, 3588-3597.	0.6	104
75	Ruxolitinib for the treatment of patients with polycythemia vera. Expert Review of Hematology, 2015, 8, 391-401.	1.0	10
76	CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis. Molecular Cancer Therapeutics, 2015, 14, 1717-1727.	1.9	71
77	The interferon-alpha revival in CML. Annals of Hematology, 2015, 94, 195-207.	0.8	57
78	Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia InÂVivo. Cancer Cell, 2015, 27, 589-602.	7.7	290
79	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA - Journal of the American Medical Association, 2015, 314, 913.	3.8	333
80	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood, 2014, 124, 1038-1046.	0.6	192
81	Ponatinib in Philadelphia Chromosome–Positive Leukemias. New England Journal of Medicine, 2014, 370, 577-577.	13.9	24
82	Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3550-3555.	3.3	74
83	Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leukemia Research, 2014, 38, 10-20.	0.4	146
84	Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I). Bioorganic and Medicinal Chemistry, 2014, 22, 1450-1458.	1.4	12
85	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 2014, 99, 292-298.	1.7	38
86	A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers. Blood, 2014, 124, 1842-1842.	0.6	1
87	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. Blood, 2014, 124, 3135-3135.	0.6	43
88	Impact of Dose Intensity of Ponatinib on Selected Adverse Events: Multivariate Analyses from a Pooled Population of Clinical Trial Patients. Blood, 2014, 124, 4546-4546.	0.6	15
89	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. Blood, 2014, 124, 4552-4552.	0.6	8
90	Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias Journal of Clinical Oncology, 2014, 32, 7084-7084.	0.8	13

#	Article	IF	CITATIONS
91	Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget, 2014, 5, 5559-5569.	0.8	51
92	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemotherapy and Pharmacology, 2013, 71, 1599-1607.	1.1	23
93	Identification of Targetable FGFR Gene Fusions in Diverse Cancers. Cancer Discovery, 2013, 3, 636-647.	7.7	614
94	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nature Genetics, 2013, 45, 180-185.	9.4	662
95	Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 2013, 31, 1285-1292.	0.8	171
96	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nature Genetics, 2013, 45, 1446-1451.	9.4	925
97	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placeboâ€controlled, Phase <scp>III</scp> study in patients with myelofibrosis. British Journal of Haematology, 2013, 161, 508-516.	1.2	83
98	Hematology clinic: chronic myelogenous leukemia. Hematology, 2013, 18, 372-373.	0.7	0
99	Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica, 2013, 98, 217-221.	1.7	65
100	Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. Journal of Hematology and Oncology, 2013, 6, 81.	6.9	89
101	Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. British Journal of Haematology, 2013, 162, 548-552.	1.2	54
102	Re-emergence of interferon-Î \pm in the treatment of chronic myeloid leukemia. Leukemia, 2013, 27, 803-812.	3.3	123
103	Overcoming resistance in chronic myeloid leukemia. Clinical Investigation, 2013, 3, 817-821.	0.0	0
104	Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica, 2013, 98, 1865-1871.	1.7	143
105	Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). Blood, 2013, 122, 1496-1496.	0.6	4
106	Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. Blood, 2013, 122, 650-650.	0.6	8
107	Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). Blood, 2013, 122, 652-652.	0.6	6
108	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, 2012, 119, 1981-1987.	0.6	298

#	Article	IF	CITATIONS
109	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New England Journal of Medicine, 2012, 366, 799-807.	13.9	1,738
110	Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias. New England Journal of Medicine, 2012, 367, 2075-2088.	13.9	668
111	A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. Blood, 2012, 120, 163-163.	0.6	34
112	A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF Blood, 2012, 120, 2837-2837.	0.6	10
113	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. Blood, 2012, 120, 3747-3747.	0.6	6
114	Managing resistance in chronic myeloid leukemia. Blood Reviews, 2011, 25, 279-290.	2.8	56
115	Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood, 2011, 117, 3151-3162.	0.6	105
116	Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood, 2011, 118, 3051-3061.	0.6	105
117	NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-25.	2.3	37
118	Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity. Biochemical Pharmacology, 2011, 82, 341-349.	2.0	35
119	Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. Bioorganic and Medicinal Chemistry, 2011, 19, 7194-7204.	1.4	7
120	A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cellular Signalling, 2011, 23, 2076-2085.	1.7	38
121	Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. Science Translational Medicine, 2011, 3, 111ra121.	5.8	531
122	Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. Journal of Clinical Oncology, 2011, 29, 789-796.	0.8	369
123	Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood, 2010, 116, 4958-4967.	0.6	65
124	Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochemical Pharmacology, 2010, 79, 688-697.	2.0	27
125	NF1 Inactivation in Adult Acute Myelogenous Leukemia. Clinical Cancer Research, 2010, 16, 4135-4147.	3.2	66
126	Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis. Cancer Research, 2010, 70, 9265-9276.	0.4	321

#	Article	IF	CITATIONS
127	PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal. PLoS ONE, 2010, 5, e11770.	1.1	29
128	Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate. Clinical Cancer Research, 2009, 15, 3850-3855.	3.2	25
129	Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology, 2009, 27, 5015-5022.	0.8	74
130	Following the Hedgehog to New Cancer Therapies. New England Journal of Medicine, 2009, 361, 1202-1205.	13.9	53
131	Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology American Society of Hematology Education Program, 2009, 2009, 461-476.	0.9	153
132	Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 984-1023.	2.3	151
133	Inhibition of Cytokine Signaling through Activation of Jak2 Ubiquitination by WP1130 Blood, 2009, 114, 2907-2907.	0.6	0
134	De-Ubiquitinase Inhibition by WP1130 Induces Formation of Aggresomes, Engages Autophagy and Activates Apoptosis in B-Cell Malignancies Blood, 2009, 114, 3769-3769.	0.6	6
135	WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells Blood, 2009, 114, 3303-3303.	0.6	0
136	Cell-cycle deregulation in progressive CML. Nature Reviews Cancer, 2008, 8, 563-563.	12.8	0
137	Getting to the stem of chronic myeloid leukaemia. Nature Reviews Cancer, 2008, 8, 341-350.	12.8	167
138	The Fine Tuning of Therapy for Chronic Myeloid Leukemia and Upcoming Challenges. Clinical Lymphoma and Myeloma, 2008, 8, S74.	1.4	0
139	Efficacy of Various Doses and Schedules of Second-Generation Tyrosine Kinase Inhibitors. Clinical Lymphoma and Myeloma, 2008, 8, S95-S106.	1.4	7
140	Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation. Clinical Leukemia, 2008, 2, 267-271.	0.2	3
141	Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood, 2008, 111, 1584-1593.	0.6	107
142	Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase. Journal of the National Cancer Institute, 2008, 100, 926-939.	3.0	149
143	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-î± treatment. Blood, 2008, 111, 1039-1043.	0.6	195
144	Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood, 2008, 111, 3821-3829.	0.6	97

#	Article	IF	CITATIONS
145	Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. Blood, 2008, 112, 3232-3232.	0.6	29
146	Degrasyn (a novel tyrophostin) Impacts BCR-ABL Protein Level and Is Cytotoxic to Chronic Myeloid Leukemia Early Progenitors. Blood, 2008, 112, 3212-3212.	0.6	0
147	Degrasyn Activates Proteasomal-Dependent Degradation of c-Myc. Cancer Research, 2007, 67, 3912-3918.	0.4	40
148	Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood, 2007, 109, 3470-3478.	0.6	82
149	Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood, 2007, 109, 497-499.	0.6	150
150	The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine and Growth Factor Reviews, 2007, 18, 459-471.	3.2	71
151	Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leukemia and Lymphoma, 2007, 48, 2310-2322.	0.6	32
152	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 2007, 109, 4143-4150.	0.6	352
153	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer, 2007, 109, 1556-1560.	2.0	89
154	Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy Blood, 2007, 110, 1938-1938.	0.6	4
155	Dasatinib Resistance in CML Patients. Identification of Novel BCR-ABL Kinase Domain Mutation Blood, 2007, 110, 1957-1957.	0.6	2
156	Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia Blood, 2007, 110, 224-224.	0.6	0
157	A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling Blood, 2007, 110, 1556-1556.	0.6	0
158	Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation Blood, 2007, 110, 1003-1003.	0.6	1
159	Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias. New England Journal of Medicine, 2006, 354, 2531-2541.	13.9	1,606
160	New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance. Annals of Internal Medicine, 2006, 145, 913.	2.0	216
161	Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: Implications for imatinib mesylate response and resistance. Leukemia and Lymphoma, 2006, 47, 1651-1664.	0.6	4
162	Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood, 2006, 107, 2501-2506.	0.6	76

#	Article	IF	CITATIONS
163	The TNF receptor, RELT, binds SPAK and uses it to mediate p38 and JNK activation. Biochemical and Biophysical Research Communications, 2006, 343, 125-134.	1.0	40
164	TRAIL-induced cleavage and inactivation of SPAK sensitizes cells to apoptosis. Biochemical and Biophysical Research Communications, 2006, 349, 1016-1024.	1.0	11
165	Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood, 2006, 108, 1835-1840.	0.6	204
166	Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer, 2006, 106, 346-352.	2.0	67
167	Staging of chronic myeloid leukemia in the imatinib era. Cancer, 2006, 106, 1306-1315.	2.0	107
168	Immune restoration and/or augmentation of local graft versus host reaction by traditional chinese medicinal herbs. Cancer, 2006, 52, 70-73.	2.0	39
169	Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib. Journal of Clinical Oncology, 2006, 24, 1204-1208.	0.8	210
170	Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism Blood, 2006, 108, 3423-3423.	0.6	0
171	Bortezomib Synergizes with a Novel Jak2 Inhibitor, WP-1130, To Inhibit Cell Growth and Induce Apoptosis in "Classic―and "Blastoid-Variant―Mantle Cell Lymphoma Blood, 2006, 108, 2512-2512.	0.6	Ο
172	Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance Blood, 2006, 108, 4819-4819.	0.6	0
173	A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia Blood, 2006, 108, 4773-4773.	0.6	0
174	Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells Blood, 2006, 108, 2132-2132.	0.6	0
175	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood, 2005, 105, 2281-2286.	0.6	102
176	Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia—Comparison with historic experience. Cancer, 2005, 103, 2099-2108.	2.0	63
177	Interferon \hat{I}_{\pm} therapy for patients with essential thrombocythemia. Cancer, 2005, 103, 2551-2557.	2.0	21
178	Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer, 2005, 104, 777-780.	2.0	24
179	Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia. Clinical Cancer Research, 2005, 11, 6247-6255.	3.2	33
180	Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate. Journal of Clinical Oncology, 2005, 23, 3948-3956.	0.8	290

#	Article	IF	CITATIONS
181	Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate. Clinical Cancer Research, 2005, 11, 3425-3432.	3.2	256
182	Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells. Clinical Cancer Research, 2005, 11, 6924-6932.	3.2	315
183	Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment. Mayo Clinic Proceedings, 2005, 80, 390-402.	1.4	55
184	The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leukemia and Lymphoma, 2005, 46, 993-997.	0.6	30
185	Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls. Clinical Cancer Research, 2004, 10, 68-75.	3.2	56
186	Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia. Cancer Research, 2004, 64, 672-677.	0.4	210
187	Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. British Journal of Haematology, 2004, 125, 187-195.	1.2	88
188	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer, 2004, 100, 116-121.	2.0	111
189	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer, 2004, 100, 2592-2597.	2.0	59
190	Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer, 2004, 100, 2396-2402.	2.0	35
191	Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer, 2004, 101, 332-336.	2.0	66
192	Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients. Journal of Clinical Oncology, 2004, 22, 935-942.	0.8	426
193	Investigational strategies in chronic myelogenous leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 619-639.	0.9	8
194	The Role of Imatinib in the Treatment of Chronic Myelogenous Leukemia. American Journal of Cancer, 2004, 3, 337-348.	0.4	0
195	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia. Blood, 2004, 103, 2873-2878.	0.6	369
196	Nuclear factor–κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood, 2004, 103, 3175-3184.	0.6	306
197	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood, 2004, 103, 4396-4407.	0.6	522
198	Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood, 2004, 104, 1979-1988.	0.6	163

#	Article	IF	CITATIONS
199	Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study Blood, 2004, 104, 1-1.	0.6	45
200	Hematologic and Cytogenetic Responses in Imatinib-Resistant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study Blood, 2004, 104, 20-20.	0.6	19
201	Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance Blood, 2004, 104, 2097-2097.	0.6	2
202	Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials Blood, 2004, 104, 23-23.	0.6	61
203	Complete cytogenetic and molecular responses to interferon-?-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer, 2003, 97, 1033-1041.	2.0	219
204	Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 2003, 97, 2225-2228.	2.0	26
205	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 2003, 97, 2760-2766.	2.0	107
206	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer, 2003, 97, 3010-3016.	2.0	10
207	Sudden onset of the blastic phase of chronic myelogenous leukemia. Cancer, 2003, 98, 81-85.	2.0	48
208	Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer, 2003, 98, 437-457.	2.0	84
209	Results of decitabine (5-aza-2?deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer, 2003, 98, 522-528.	2.0	230
210	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer, 2003, 98, 888-893.	2.0	69
211	Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 2003, 98, 1105-1113.	2.0	85
212	Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-? regimens for early chronic phase. Cancer, 2003, 98, 1430-1437.	2.0	19
213	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer, 2003, 98, 1905-1911.	2.0	124
214	Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer, 2003, 98, 2410-2419.	2.0	21
215	Imatinib mesylate causes hypopigmentation in the skin. Cancer, 2003, 98, 2483-2487.	2.0	143
216	Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase. Cancer, 2003, 98, 2636-2642.	2.0	89

#	Article	IF	CITATIONS
217	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia Research, 2003, 27, 1091-1096.	0.4	23
218	Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics. Annals of Internal Medicine, 2003, 138, 819.	2.0	259
219	BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 2003, 101, 690-698.	0.6	630
220	TWEAK Mediates Signal Transduction and Differentiation of RAW264.7 Cells in the Absence of Fn14/TweakR. Journal of Biological Chemistry, 2003, 278, 32317-32323.	1.6	130
221	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 2003, 101, 473-475.	0.6	304
222	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 2003, 101, 1692-1697.	0.6	210
223	Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood, 2003, 101, 3794-3800.	0.6	215
224	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood, 2003, 102, 4527-4534.	0.6	129
225	Resveratrol blocks interleukin-1β–induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood, 2003, 102, 987-995.	0.6	307
226	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome—positive chronic myeloid leukemia after failure of interferon-α. Blood, 2003, 102, 83-86.	0.6	174
227	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome–positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood, 2003, 101, 97-100.	0.6	147
228	Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood, 2003, 102, 630-637.	0.6	51
229	Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clinical Cancer Research, 2003, 9, 160-6.	3.2	77
230	Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clinical Cancer Research, 2003, 9, 976-80.	3.2	75
231	Current Therapy of Chronic Myelogenous Leukemia Internal Medicine, 2002, 41, 254-264.	0.3	16
232	Imatinib mesylate (STI571) therapy for Philadelphia chromosome–positive chronic myelogenous leukemia in blast phase. Blood, 2002, 99, 3547-3553.	0.6	282
233	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002, 99, 1928-1937.	0.6	943
234	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 2002, 99, 3530-3539.	0.6	1,096

#	Article	IF	CITATIONS
235	Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. New England Journal of Medicine, 2002, 346, 645-652.	13.9	1,899
236	Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood, 2002, 100, 1590-1595.	0.6	153
237	Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer, 2002, 94, 1517-1521.	2.0	22
238	Simultaneous homoharringtonine and interferon- $\hat{l}\pm$ in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer, 2002, 94, 2024-2032.	2.0	65
239	Neutrophilic-chronic myeloid leukemia. Cancer, 2002, 94, 2416-2425.	2.0	66
240	Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Cancer, 2002, 94, 2996-2999.	2.0	20
241	Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. Cancer, 2002, 95, 440-450.	2.0	24
242	Severe periorbital edema secondary to STI571 (Gleevec). Cancer, 2002, 95, 881-887.	2.0	129
243	CELLULAR SIGNALLING PATHWAYS: NEW TARGETS IN LEUKAEMIA THERAPY. British Journal of Haematology, 2002, 116, 57-77.	1.2	25
244	Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. British Journal of Haematology, 2002, 119, 38-45.	1.2	39
245	Sti-571 in Chronic Myelogenous Leukaemia. British Journal of Haematology, 2002, 119, 15-24.	1.2	23
246	Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clinical Cancer Research, 2002, 8, 2167-76.	3.2	84
247	Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clinical Cancer Research, 2002, 8, 2177-87.	3.2	97
248	Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. New England Journal of Medicine, 2001, 344, 1031-1037.	13.9	4,825
249	Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome. New England Journal of Medicine, 2001, 344, 1038-1042.	13.9	2,593
250	Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biology of Blood and Marrow Transplantation, 2001, 7, 568-575.	2.0	55
251	Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. Seminars in Hematology, 2001, 38, 22-27.	1.8	24
252	Results of Therapy with Interferon Alpha and Cyclic Combination Chemotherapy in Patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Early Chronic Phase. Leukemia and Lymphoma, 2001, 41, 309-319.	0.6	12

#	Article	IF	CITATIONS
253	<i>BCR</i> Rearrangement–Negative Chronic Myelogenous Leukemia Revisited. Journal of Clinical Oncology, 2001, 19, 2915-2926.	0.8	98
254	Pilot Study of Low-Dose Interleukin-11 in Patients With Bone Marrow Failure. Journal of Clinical Oncology, 2001, 19, 4165-4172.	0.8	61
255	Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon α: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood, 2001, 97, 2791-2797.	0.6	16
256	Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood, 2001, 98, 1773-1781.	0.6	62
257	Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor β-chain in BCR-ABL+human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood, 2001, 97, 2846-2853.	0.6	48
258	Phase 1 study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome–positive chronic myelogenous leukemia. Blood, 2001, 98, 1708-1713.	0.6	69
259	Chronic myelogenous leukemia in chronic phase. Current Treatment Options in Oncology, 2001, 2, 245-252.	1.3	7
260	Translocation t(17;18)(q10;q10). Cancer, 2001, 91, 1704-1708.	2.0	7
261	Expression of apoptosis proteins in chronic myelogenous leukemia. Cancer, 2001, 91, 1964-1972.	2.0	39
262	Homoharringtonine. Cancer, 2001, 92, 1591-1605.	2.0	177
263	Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer, 2001, 92, 2501-2507.	2.0	20
264	Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias. Seminars in Oncology, 2001, 28, 9-18.	0.8	39
265	Imatinib mesylate: Clinical results in philadelphia chromosome-positive leukemias. Seminars in Oncology, 2001, 28, 9-18.	0.8	115
266	Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB Journal, 2000, 14, 1529-1538.	0.2	26
267	Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. Hematology American Society of Hematology Education Program, 2000, 2000, 90-109.	0.9	17
268	Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia. , 2000, 88, 570-576.		11
269	Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-?. Cancer, 2000, 89, 1482-1489.	2.0	22
270	Therapeutic choices in younger patients with chronic myelogenous leukemia. Cancer, 2000, 89, 1647-1658.	2.0	22

#	Article	IF	CITATIONS
271	Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins. Leukemia, 2000, 14, 1892-1897.	3.3	6
272	Cellâ€penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB Journal, 2000, 14, 1529-1538.	0.2	45
273	Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia. Journal of Clinical Oncology, 2000, 18, 3513-3521.	0.8	81
274	Acute Pancreatitis Associated with Interferon Alpha Therapy for Chronic Myelogenous Leukemia. Leukemia and Lymphoma, 2000, 39, 647-650.	0.6	11
275	Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. Hematology American Society of Hematology Education Program, 2000, 2000, 90-109.	0.9	1
276	Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. Hematology American Society of Hematology Education Program, 2000, 2000, 90-109.	0.9	5
277	Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine. Journal of Clinical Oncology, 1999, 17, 284-284.	0.8	135
278	Phenylarsine Oxide Blocks Interleukin-1β–Induced Activation of the Nuclear Transcription Factor NF-κB, Inhibits Proliferation, and Induces Apoptosis of Acute Myelogenous Leukemia Cells. Blood, 1999, 94, 2844-2853.	0.6	72
279	Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia. Blood, 1999, 93, 4149-4153.	0.6	97
280	Methylation of the ABL1 Promoter in Chronic Myelogenous Leukemia: Lack of Prognostic Significance. Blood, 1999, 93, 2075-2080.	0.6	67
281	Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making?. Blood, 1999, 93, 2755-2759.	0.6	79
282	Unexpected High Incidence of Severe Toxicities Associated with Alpha Interferon, Low-Dose Cytosine Arabinoside and All-Trans Retinoic Acid in Patients with Chronic Myelogenous Leukemia. Leukemia and Lymphoma, 1999, 35, 483-489.	0.6	13
283	A Pilot Study of Recombinant Human Interleukin-4 Therapy of Myelofibrosis. Journal of Interferon and Cytokine Research, 1999, 19, 1253-1255.	0.5	2
284	Chronic myelogenous leukaemia with p185 BCR/ABL expression: characteristics and clinical significance. British Journal of Haematology, 1999, 107, 581-586.	1.2	59
285	Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia. Cancer, 1999, 85, 2583-2588.	2.0	51
286	Multidrug resistance protein expression in chronic myeloid leukemia. , 1999, 86, 805-813.		33
287	Chronic myelogenous leukemia in nonlymphoid blastic phase. , 1999, 86, 2632-2641.		167
288	Chronic Myelogenous Leukemia: Biology and Therapy. Annals of Internal Medicine, 1999, 131, 207.	2.0	382

#	Article	IF	CITATIONS
289	The Biology of Chronic Myeloid Leukemia. New England Journal of Medicine, 1999, 341, 164-172.	13.9	1,126
290	Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making?. Blood, 1999, 93, 2755-2759.	0.6	32
291	Sequential Homoharringtonine and Interferon- in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia. Blood, 1999, 93, 4149-4153.	0.6	18
292	DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. Leukemia, 1998, 12, 242-246.	3.3	2
293	GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia, 1998, 12, 860-864.	3.3	43
294	Interleukin-1 increases expression of the LYT-10 (NFκB2) proto-oncogene/transcription factor in renal cell carcinoma lines. Translational Research, 1998, 131, 261-268.	2.4	4
295	Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leukemia Research, 1998, 22, 341-353.	0.4	32
296	CLINICAL COURSE AND THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA WITH INTERFERON-ALPHA AND CHEMOTHERAPY. Hematology/Oncology Clinics of North America, 1998, 12, 31-80.	0.9	58
297	Local Cutaneous Necrotizing Lesions Associated with Interferon Injections. Journal of Interferon and Cytokine Research, 1998, 18, 823-827.	0.5	17
298	Serum Cytokine Levels in Infectious Mononucleosis at Diagnosis and Convalescence. Leukemia and Lymphoma, 1998, 30, 583-589.	0.6	21
299	Thrombopoietin Stimulates Myelodysplastic Syndrome Granulocyte-Macrophage and Erythroid Progenitor Proliferation. Leukemia and Lymphoma, 1998, 30, 279-292.	0.6	13
300	High Serum Interleukin-6 Levels Correlate with a Shorter Failure-Free Survival in Indolent Lymphoma. Leukemia and Lymphoma, 1998, 30, 563-571.	0.6	41
301	Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity Journal of Clinical Oncology, 1998, 16, 1526-1531.	0.8	59
302	Caspase 2 and Caspase 3 Protein Levels as Predictors of Survival in Acute Myelogenous Leukemia. Blood, 1998, 92, 3090-3097.	0.6	127
303	Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia. Blood, 1998, 91, 3995-4019.	0.6	287
304	Loss of Imprinting in Disease Progression in Chronic Myelogenous Leukemia. Blood, 1998, 91, 3144-3147.	0.6	76
305	Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia. Blood, 1998, 91, 3995-4019.	0.6	92
306	Apoptosis in Chronic Myelogenous Leukemia: Studies of Stage-Specific Differences. Leukemia and Lymphoma, 1997, 25, 121-133.	0.6	14

#	Article	IF	CITATIONS
307	Role of Interleukin-1β Converting Enzyme (ICE) in Acute Myelogenous Leukemia Cell Proliferation and Programmed Cell Death. Leukemia and Lymphoma, 1997, 24, 379-391.	0.6	6
308	Second cancer risk in hairy cell leukemia: analysis of 350 patients Journal of Clinical Oncology, 1997, 15, 1803-1810.	0.8	101
309	Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma. Annals of Internal Medicine, 1997, 127, 186.	2.0	98
310	Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in in in in in in in in interferon-α-resistant hairy cell leukemia: 7-year follow-up. Leukemia, 1997, 11, 42-47.	3.3	72
311	6 Natural history and staging of chronic myelogenous leukaemia. Best Practice and Research: Clinical Haematology, 1997, 10, 277-290.	1.1	19
312	7 The M.D. Anderson Cancer Center experience with interferon-α therapy in chronic myelogenous leukaemia. Best Practice and Research: Clinical Haematology, 1997, 10, 291-305.	1.1	9
313	Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. Leukemia Research, 1997, 21, 519-527.	0.4	2
314	Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. , 1997, 80, 396-400.		2
315	Chronic myelogenous leukemia: A review. American Journal of Medicine, 1996, 100, 555-570.	0.6	151
316	Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. American Journal of Medicine, 1996, 100, 452-455.	0.6	40
317	Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia. Gene, 1996, 169, 173-178.	1.0	7
318	Comparison of <i>bcr-abl</i> Protein Expression and Philadelphia Chromosome Analyses in Chronic Myelogenous Leukemia Patients. American Journal of Clinical Pathology, 1996, 106, 442-448.	0.4	19
319	Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: Implications for the treatment of patients with metastatic melanoma. Cancer, 1996, 77, 893-899.	2.0	23
320	Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. , 1996, 66, 515-519.		75
321	Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: Studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). , 1996, 166, 618-630.		28
322	Practical Guidelines for the Management of Chronic Myelogenous Leukemia with Interferon Alpha. Leukemia and Lymphoma, 1996, 23, 247-252.	0.6	28
323	Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long term follow-up results. Cancer, 1995, 75, 464-470.	2.0	54
324	Abnormalities in thePRAD1 (CYCLIN D1 /BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. Cancer, 1995, 75, 584-590.	2.0	48

#	Article	IF	CITATIONS
325	Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. Cancer, 1995, 76, 609-617.	2.0	33
326	The breakpoint cluster region site in patients with Philadelphia chromosome–positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. Cancer, 1995, 76, 992-997.	2.0	28
327	Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leukemia Research, 1995, 19, 23-34.	0.4	50
328	Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma Journal of Clinical Oncology, 1995, 13, 575-582.	0.8	164
329	Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3488-3492.	3.3	18
330	Interferon-α directly inhibits DNA polymerase activity in isolated chromatin nucleoprotein complexes: correlation with IFN-α treatment outcome in patients with chronic myelogenous leukemia. Gene, 1995, 159, 105-111.	1.0	7
331	Elevated Plasma Thrombopoietic Activity in Patients With Metastatic Cancer-Related Thrombocytosis. American Journal of Medicine, 1995, 98, 551-558.	0.6	61
332	Interferon-α therapy for chronic myelogenous leukemia. American Journal of Medicine, 1995, 99, 402-411.	0.6	46
333	Leukemia Inhibitory Factor Binds to Human Breast Cancer Cells and Stimulates Their Proliferation. Journal of Interferon and Cytokine Research, 1995, 15, 905-913.	0.5	47
334	Low-Dose Interferon-Î \pm in Chronic Myeloid Leukemia. Annals of Internal Medicine, 1995, 122, 728.	2.0	3
335	The Use of Growth Factor Receptor Inhibitors in Human Neoplasms. , 1994, , 178-195.		0
336	Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors. Stem Cells, 1994, 12, 638-649.	1.4	6
337	What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia?. American Journal of Medicine, 1994, 96, 133-138.	0.6	12
338	Granulocyteâ€macrophage colonyâ€stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. Journal of Internal Medicine, 1993, 234, 417-420.	2.7	60
339	Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. Stem Cells, 1993, 11, 112-119.	1.4	17
340	Therapy of chronic myelogenous leukemia. Stem Cells, 1993, 11, 8-9.	1.4	5
341	Molecular approaches to the diagnosis and treatment of cancer. Stem Cells, 1993, 11, 129-130.	1.4	1
342	Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. American Journal of Medicine, 1993, 94, 69-74.	0.6	101

#	Article	IF	CITATIONS
343	Use of Two Retroviral Markers to Test Relative Contribution of Marrow and Peripheral Blood Autologous Cells to Recovery After Preparative Therapy. The University of Texas M.D. Anderson Cancer Center. Human Gene Therapy, 1993, 4, 71-85.	1.4	13
344	Genetic Therapy of Human Neoplastic Disease. Stem Cells and Development, 1993, 2, 373-375.	1.0	0
345	CML: Mechanisms of Disease Initiation and Progression. Leukemia and Lymphoma, 1993, 11, 47-50.	0.6	26
346	Long-Term Follow-Up Results of Alpha Interferon Therapy in Chronic Myelogenous Leukemia at M. D. Anderson Cancer Center. Leukemia and Lymphoma, 1993, 11, 169-174.	0.6	9
347	Role of Interleukin-1 Inhibitory Molecules in Therapy of Acute and Chronic Myelogenous Leukemia. Leukemia and Lymphoma, 1993, 10, 407-418.	0.6	15
348	Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines Journal of Experimental Medicine, 1993, 177, 763-774.	4.2	79
349	All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome Journal of Clinical Oncology, 1993, 11, 1489-1495.	0.8	55
350	Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation Journal of Clinical Investigation, 1993, 92, 1925-1939.	3.9	163
351	New Directions in the Biology and Therapy of Chronic Myeloid Leukemia. Leukemia and Lymphoma, 1992, 6, 89-95.	0.6	5
352	Use of Cell-Free Retroviral Vector Preparations for Transduction of Cells from the Marrow of Chronic Phase and Blast Crisis Chronic Myelogenous Leukemia Patients and from Normal Individuals. Human Gene Therapy, 1992, 3, 137-145.	1.4	18
353	The Modulatory Hematopoietic Activities of Leukemia Inhibitory Factor. Leukemia and Lymphoma, 1992, 8, 1-7.	0.6	5
354	Identification of a Complex Formed Between Nuclear Proteins and the Transcriptional Enhancer of Interferon-Inducible Genes That Is Present in the Peripheral Blood Myeloid Cells of CML but Not Normal Individuals. Journal of Interferon Research, 1992, 12, 323-327.	1.2	0
355	Very low doses of GM-CSF administered alone or with erythropoietin in a plastic anemia. American Journal of Medicine, 1992, 93, 41-48.	0.6	27
356	Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer, 1992, 69, 410-412.	2.0	25
357	Treatment of cyclic neutropenia with very low doses of GM-CSF. American Journal of Medicine, 1991, 91, 317-318.	0.6	16
358	Phase I study of recombinant human interleukin-3 in patients with bone marrow failure Journal of Clinical Oncology, 1991, 9, 1241-1250.	0.8	140
359	Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia. Annals of Internal Medicine, 1991, 114, 532.	2.0	365
360	Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients. British Journal of Haematology, 1991, 78, 352-358.	1.2	32

#	Article	IF	CITATIONS
361	Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines. British Journal of Haematology, 1991, 78, 359-367.	1.2	5
362	Hairy cell leukaemia: review of treatment. British Journal of Haematology, 1991, 79, 17-20.	1.2	19
363	The molecular pathology of chronic myelogenous leukaemia. British Journal of Haematology, 1991, 79, 34-37.	1.2	20
364	Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. British Journal of Haematology, 1991, 77, 291-295.	1.2	74
365	Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer, 1991, 67, 990-996.	2.0	97
366	Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission. Cancer, 1991, 67, 1946-1949.	2.0	9
367	Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of philadelphia chromosome-negative cells in chronic myelogenous leukemia. Cancer, 1991, 67, 2959-2965.	2.0	32
368	Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 1991, 68, 1201-1207.	2.0	45
369	Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer, 1991, 68, 1536-1537.	2.0	120
370	A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. Cancer, 1991, 68, 2125-2130.	2.0	24
371	Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: A potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. Annals of Hematology, 1991, 63, 297-301.	0.8	10
372	Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. Cancer Immunology, Immunotherapy, 1991, 33, 238-246.	2.0	15
373	A phase I trial of recombinant alpha-2a Interferon (Roferon-A) with weekly cisplatinum. Investigational New Drugs, 1991, 9, 37-9.	1.2	14
374	Molecular Analysis of Retroviral Transduction in Chronic Myelogenous Leukemia. Human Gene Therapy, 1991, 2, 317-321.	1.4	10
375	Alpha Interferon Dose-Dependent Suppression of Secondary Clones in a Patient with Philadelphia-Positive Chronic Myelogenous Leukemia. Acta Haematologica, 1990, 83, 149-151.	0.7	4
376	Philadelphia Chromosome-Negative Chronic Myelogenous Leukemia and Chronic Myelomonocytic Leukemia. Hematology/Oncology Clinics of North America, 1990, 4, 389-404.	0.9	43
377	Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. American Journal of Medicine, 1990, 88, 1-8.	0.6	268
378	A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. American Journal of Medicine, 1990, 89, 663-672.	0.6	126

#	Article	IF	CITATIONS
379	Phase I Study of a Combination of Recombinant Tumor Necrosis Factor-α and Recombinant Interferon-γ in Cancer Patients. Journal of Interferon Research, 1989, 9, 435-444.	1.2	20
380	Therapy of Chronic Myelogenous Leukemia with Interferon. Cancer Investigation, 1989, 7, 83-91.	0.6	7
381	Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. American Journal of Medicine, 1989, 86, 554-558.	0.6	39
382	Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer, 1988, 61, 1441-1446.	2.0	245
383	Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer, 1988, 62, 672-676.	2.0	45
384	The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias. New England Journal of Medicine, 1988, 319, 990-998.	13.9	798
385	Significance and correlations of molecular analysis results in patients with philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. American Journal of Medicine, 1988, 85, 639-644.	0.6	43
386	Clinical studies of alpha-interferons in chronic myelogenous leukemia. Cancer Treatment Reviews, 1988, 15, 49-53.	3.4	2
387	Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy Journal of Clinical Oncology, 1988, 6, 1569-1575.	0.8	44
388	Malignancy-associated Sweet's syndrome: review of the world literature Journal of Clinical Oncology, 1988, 6, 1887-1897.	0.8	349
389	A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients Journal of Clinical Oncology, 1988, 6, 1328-1334.	0.8	210
390	Characteristics of accelerated disease in chronic myelogenous leukemia. , 1988, 61, 1441.		1
391	Clinical Studies of Alpha and Gamma Interferons in Chronic Myelogenous Leukemia. , 1988, , 127-139.		0
392	Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genetics and Cytogenetics, 1987, 27, 349-356.	1.0	39
393	Chronic myelogenous leukemia in blast crisis. American Journal of Medicine, 1987, 83, 445-454.	0.6	270
394	Intensive Combination Chemotherapy and Interferons in the Management of Chronic Myelogenous Leukemia. Acta Haematologica, 1987, 78, 70-74.	0.7	6
395	Clinical and prognostic features of patients with philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. Cancer, 1987, 59, 297-300.	2.0	51
396	Therapy of chronic myelogenous leukemia. Cancer, 1987, 59, 664-667.	2.0	27

#	Article	IF	CITATIONS
397	The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer, 1987, 59, 1739-1743.	2.0	80
398	Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer, 1987, 60, 1708-1712.	2.0	29
399	Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia-a pilot study. American Journal of Hematology, 1987, 24, 341-350.	2.0	41
400	Molecular analysis of chromosome 22 breakpoints in adult Philadelphiaâ€positive acute lymphoblastic leukaemia. British Journal of Haematology, 1987, 67, 55-59.	1.2	2
401	Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. British Journal of Haematology, 1987, 67, 55-59.	1.2	35
402	Rearrangement in the Breakpoint Cluster Region and the Clinical Course in Philadelphia-Negative Chronic Myelogenous Leukemia. Annals of Internal Medicine, 1986, 105, 673.	2.0	67
403	Phase I study of multiple dose intramuscularly administered recombinant gamma interferon Journal of Clinical Oncology, 1986, 4, 1101-1109.	0.8	88
404	Clinical toxicity of interferons in cancer patients: a review Journal of Clinical Oncology, 1986, 4, 234-243.	0.8	610
405	Clinical and prognostic features of philadelphia chromosome-negative chronic myelogenous leukemia. Cancer, 1986, 58, 2023-2030.	2.0	66
406	Chronic myelogenous leukaemia: haematological remissions with alpha interferon. British Journal of Haematology, 1986, 64, 87-95.	1.2	65
407	Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon Alpha _A in Chronic Myelogenous Leukemia. New England Journal of Medicine, 1986, 314, 1065-1069.	13.9	683
408	Pharmacokinetics, Single-Dose Tolerance, and Biological Activity of Recombinant Gamma-Interferon in Cancer Patients. Oncology, 1985, 42, 41-50.	0.9	16
409	Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFNα) therapy. International Journal of Cancer, 1985, 36, 23-28.	2.3	42
410	The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology, 1985, 140, 230-238.	1.1	176
411	Rheumatoid factors in the sera of patients with gastrointestinal carcinoma. Cancer, 1983, 52, 2156-2161.	2.0	20
412	Objective evaluation of local xenogeneic graft-versus-host reaction by Computerized radioisotope imaging (CRI). Journal of Immunological Methods, 1983, 61, 133-139.	0.6	0
413	The immune restorative effect of isoprinosine administration on the local graft-versus-host reaction of cancer patients. Clinical Immunology and Immunopathology, 1983, 28, 96-100.	2.1	5
414	Human Leukocyte Interferon to Control Thrombocytosis in Chronic Myelogenous Leukemia. Annals of Internal Medicine, 1983, 99, 789.	2.0	85

#	Article	IF	CITATIONS
415	The immune restorative effect of cimetidine administration in vivo on the local graft-versus-host reaction of cancer patients. Clinical Immunology and Immunopathology, 1982, 24, 155-160.	2.1	39
416	Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among	2.0	17

Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remission. Cancer Immunology, Immunotherapy, 1982, 14, 96-8. 416